Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17745
Country/Region: Nigeria
Year: 2014
Main Partner: Achieving Health Nigeria Initiative
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $1,255,480 Additional Pipeline Funding: N/A

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

This narrative covers COP14 and COP15 activities to be implemented by the Sustaining Comprehensive HIV/AIDS Response through Partnerships (SCHARP Plus) project. Under PEPFAR, the United States Government has awarded AHNi the five year SCHARP Plus Project which commenced July 1, 2013. The goal of the project is to attain sustainable local partnership of comprehensive HIV/AIDS prevention, care and treatment program in Ogun and Oyo state by the end of project period. To achieve this goal, the project will pursue the following objectives: 1) primary prevention of HIV infection; 2) improve the quality of care and treatment of HIV/AIDS, STIs, and related opportunistic infections and 3) improve stewardship by Nigerian institutions for the provision of high-quality comprehensive HIV/AIDS services.

AHNi proposes practical, cost-effective, and sustainable interventions and programs to continue the provision of HIV/AIDS services initiated under the PEPFAR funded HHS/CDC. As a Prime, AHNi will emphasize doing more with limited resources at its disposal. Most trainings of HCWs will be facility based. AHNi will continue to advocate to government to address human resource gaps and provision of infrastructure in supported sites.

SCHARP Plus is designed with a focus on service integration; local ownership; and quality - with all interventions delivered within the GON’s strategic health framework and structure that will engender ownership and fast tract transitioning of responsibilities to the government. Program and technical staff will work hand in hand with providers and managers at all levels of the health system to build their capacity “on the job” through program planning, implementation and monitoring and evaluation of program implementation.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $101,405
Care: Orphans and Vulnerable Children (HKID) $27,183
Care: TB/HIV (HVTB) $44,106
Care: Pediatric Care and Support (PDCS) $6,203
Laboratory Infrastructure (HLAB) $439,154
Biomedical Prevention: Injection Safety (HMIN) $30,000
Testing: HIV Testing and Counseling (HVCT) $74,029
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $227,172
Treatment: Adult Treatment (HTXS) $288,605
Treatment: Pediatric Treatment (PDTX) $17,623
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
FPINT_SITE By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2015 9
FPINT_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points 2015 11
FPINT_SITE Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2015 9
FPINT_SITE Sum of Numerator Site Support Type disaggregates 2015 9
FPINT_SITE Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment 2015 11
FPINT_SITE_den Sum of Denominator Site Support Type disaggregates 2015 11
GEND_GBV Age: 0-9 2015 4
GEND_GBV Age: 10-14 2015 7
GEND_GBV Age: 15-17 2015 11
GEND_GBV Age: 18-24 2015 6
GEND_GBV Age: 25+ 2015 3
GEND_GBV By PEP service provision (related to sexual violence services provided) 2015 24
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2015 7
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2015 24
GEND_GBV Number of people receiving post-GBV care 2015 31
GEND_GBV Sex: Female 2015 21
GEND_GBV Sex: Male 2015 10
GEND_GBV Sum of Age disaggregates 2015 31
GEND_GBV Sum of Sex disaggregates 2015 31
HTS_TST Age/sex: <1 Female 2015 347
HTS_TST Age/sex: <1 Female 2015 347
HTS_TST Age/sex: <1 Male 2015 334
HTS_TST Age/sex: <1 Male 2015 334
HTS_TST Age/sex: 1-4 Female 2015 148
HTS_TST Age/sex: 1-4 Female 2015 148
HTS_TST Age/sex: 1-4 Male 2015 141
HTS_TST Age/sex: 1-4 Male 2015 141
HTS_TST Age/sex: 10-14 Female 2015 131
HTS_TST Age/sex: 10-14 Female 2015 131
HTS_TST Age/sex: 10-14 Male 2015 128
HTS_TST Age/sex: 10-14 Male 2015 128
HTS_TST Age/sex: 15-19 Female 2015 3,933
HTS_TST Age/sex: 15-19 Female 2015 3,933
HTS_TST Age/sex: 15-19 Male 2015 1,418
HTS_TST Age/sex: 15-19 Male 2015 1,418
HTS_TST Age/sex: 20-24 Female 2015 11,651
HTS_TST Age/sex: 20-24 Female 2015 11,651
HTS_TST Age/sex: 20-24 Male 2015 2,936
HTS_TST Age/sex: 20-24 Male 2015 2,936
HTS_TST Age/sex: 25-49 Female 2015 23,106
HTS_TST Age/sex: 25-49 Female 2015 23,106
HTS_TST Age/sex: 25-49 Male 2015 9,223
HTS_TST Age/sex: 25-49 Male 2015 9,223
HTS_TST Age/sex: 5-9 Female 2015 59
HTS_TST Age/sex: 5-9 Female 2015 59
HTS_TST Age/sex: 5-9 Male 2015 57
HTS_TST Age/sex: 5-9 Male 2015 57
HTS_TST Age/sex: 50+ Female 2015 294
HTS_TST Age/sex: 50+ Female 2015 294
HTS_TST Age/sex: 50+ Male 2015 286
HTS_TST Age/sex: 50+ Male 2015 286
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 685
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 660
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 38,984
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 13,863
HTS_TST Aggregated Age/sex: <15 Female 2015 685
HTS_TST Aggregated Age/sex: <15 Male 2015 660
HTS_TST Aggregated Age/sex: 15+ Female 2015 38,984
HTS_TST Aggregated Age/sex: 15+ Male 2015 13,863
HTS_TST By Test Result: Negative 2015 52,874
HTS_TST By Test Result: Negative 2015 52,874
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 54,192
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 54,192
HTS_TST Sum of Age/Sex disaggregates 2015 54,192
HTS_TST Sum of Age/Sex disaggregates 2015 54,192
HTS_TST Sum of Aggregated Age/Sex <15 2015 1,345
HTS_TST Sum of Aggregated Age/Sex <15 2015 1,345
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 52,847
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 52,847
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 54,192
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 54,192
HTS_TST Sum of Test Result disaggregates 2015 54,192
HTS_TST Sum of Test Result disaggregates 2015 54,192
HTS_TST_POS By Test Result: Positive 2015 1,318
HTS_TST_POS By Test Result: Positive 2015 1,318
LAB_CAP By clinical laboratories 2015 15
LAB_CAP By site support type: Direct Service Delivery (DSD) 2015 15
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2015 15
LAB_CAP Sum of Site Support Type disaggregates 2015 15
OVC_ACC Age: <1 2015 17
OVC_ACC Age: 1-4 2015 70
OVC_ACC Age: 10-14 2015 67
OVC_ACC Age: 15-17 2015 40
OVC_ACC Age: 18+ 2015 8
OVC_ACC Age: 5-9 2015 79
OVC_ACC Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2015 281
OVC_ACC Sex: Female 2015 143
OVC_ACC Sex: Male 2015 138
OVC_ACC Sum of Age disaggregates 2015 281
OVC_ACC Sum of Sex disaggregates 2015 281
OVC_SERV Age: <1 2015 56
OVC_SERV Age: 1-4 2015 234
OVC_SERV Age: 10-14 2015 216
OVC_SERV Age: 15-17 2015 132
OVC_SERV Age: 18+ 2015 37
OVC_SERV Age: 5-9 2015 262
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2015 937
OVC_SERV Sex: Female 2015 478
OVC_SERV Sex: Male 2015 459
OVC_SERV Sum of Age disaggregates 2015 937
OVC_SERV Sum of Sex disaggregates 2015 937
PMTCT_ARV Life-long ART (including Option B+) 2015 375
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 34
PMTCT_ARV Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 265
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 744
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 681
PMTCT_ARV Single-dose nevirapine (with or without tail) 2015 7
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 248
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 127
PMTCT_ARV Sum of New and Current disaggregates 2015 375
PMTCT_ARV Sum of Regimen Type disaggregates 2015 681
PMTCT_ARV_NGI Life-long ART (including Option B+) 2015 375
PMTCT_ARV_NGI Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 34
PMTCT_ARV_NGI Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 272
PMTCT_ARV_NGI Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 748
PMTCT_ARV_NGI Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 681
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 248
PMTCT_ARV_NGI Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 127
PMTCT_ARV_NGI Sum of New and Current disaggregates 2015 375
PMTCT_ARV_NGI Sum of Regimen disaggregates 2015 681
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 225
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 456
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 34
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 748
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 681
PMTCT_EID Sum of Infant Age disaggregates 2015 681
PMTCT_STAT By: Known positives at entry 2015 299
PMTCT_STAT By: Number of new positives identified 2015 449
PMTCT_STAT Number of new ANC and L&D clients 2015 27,319
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 24,860
PMTCT_STAT Sum of Positives Status disaggregates 2015 748
PMTCT_STAT_NGI By: Known positives at entry 2015 299
PMTCT_STAT_NGI By: Number of new positives identified 2015 449
PMTCT_STAT_NGI Number of new ANC and L&D clients 2015 27,319
PMTCT_STAT_NGI Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 24,860
PMTCT_STAT_NGI Sum of Positives Status disaggregates 2015 748
SITE_SUPP By program area/support type: Lab Direct Service Delivery (DSD) 2015 3
TB_ART Age: 0-4 2015 3
TB_ART Age: 15+ 2015 282
TB_ART Age: 5-14 2015 15
TB_ART Aggregated Age: <15 2015 18
TB_ART Aggregated Age: 15+ 2015 282
TB_ART Female 2015 153
TB_ART Known HIV-positive 2015 129
TB_ART Male 2015 147
TB_ART Newly tested 2015 171
TB_ART Sum of Aggregated Age disaggregates 2015 300
TB_ART Sum of Sex disaggregates 2015 300
TB_ART Sum of Test Status disaggregates 2015 300
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2015 353
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2015 300
TB_SCREEN Age: <1 2015 97
TB_SCREEN Age: 1-4 2015 49
TB_SCREEN Age: 10-14 2015 49
TB_SCREEN Age: 15-19 2015 486
TB_SCREEN Age: 20-24 2015 1,214
TB_SCREEN Age: 25-49 2015 2,670
TB_SCREEN Age: 5-9 2015 97
TB_SCREEN Age: 50+ 2015 194
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2015 291
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2015 4,565
TB_SCREEN Sex: Female 2015 3,399
TB_SCREEN Sex: Male 2015 1,457
TB_SCREEN Sum of Age disaggregates 2015 778
TB_SCREEN Sum of Aggregated Age disaggregates 2015 4,856
TB_SCREEN Sum of Sex disaggregates 2015 4,856
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2015 4,856
TX_CURR Age/Sex: <1 Female 2015 4
TX_CURR Age/Sex: <1 Male 2015 5
TX_CURR Age/Sex: 1-4 Female 2015 21
TX_CURR Age/Sex: 1-4 Male 2015 23
TX_CURR Age/Sex: 15+ Female 2015 1,577
TX_CURR Age/Sex: 15+ Male 2015 777
TX_CURR Age/Sex: 5-14 Female 2015 38
TX_CURR Age/Sex: 5-14 Male 2015 42
TX_CURR Aggregated Age/Sex: <1 Female 2015 4
TX_CURR Aggregated Age/Sex: <1 Male 2015 5
TX_CURR Aggregated Age/Sex: <15 Female 2015 63
TX_CURR Aggregated Age/Sex: <15 Male 2015 70
TX_CURR Aggregated Age/Sex: 15+ Female 2015 1,577
TX_CURR Aggregated Age/Sex: 15+ Male 2015 777
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 2,487
TX_CURR Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 5
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 66
TX_CURR Sum of age/sex disaggregates 2015 133
TX_CURR Sum of Aggregated Age/Sex <15 2015 133
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 2,354
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 2,487
TX_CURR_NGI Age/Sex: <1 Female 2015 4
TX_CURR_NGI Age/Sex: <1 Male 2015 5
TX_CURR_NGI Age/Sex: 1-4 Female 2015 21
TX_CURR_NGI Age/Sex: 1-4 Male 2015 23
TX_CURR_NGI Age/Sex: 15+ Female 2015 1,577
TX_CURR_NGI Age/Sex: 15+ Male 2015 777
TX_CURR_NGI Age/Sex: 5-14 Female 2015 38
TX_CURR_NGI Age/Sex: 5-14 Male 2015 42
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 4
TX_CURR_NGI Aggregated Age/Sex: <1 Male 2015 5
TX_CURR_NGI Aggregated Age/Sex: <15 Female 2015 63
TX_CURR_NGI Aggregated Age/Sex: <15 Male 2015 70
TX_CURR_NGI Aggregated Age/Sex: 15+ Female 2015 1,577
TX_CURR_NGI Aggregated Age/Sex: 15+ Male 2015 777
TX_CURR_NGI Number of adults and children receiving antiretroviral therapy (ART) 2015 2,487
TX_CURR_NGI Sum of Age/Sex disaggregates 2015 2,487
TX_CURR_NGI Sum of Aggregated Age/Sex <15 2015 133
TX_CURR_NGI Sum of Aggregated Age/Sex 15+ 2015 2,354
TX_CURR_NGI Sum of Aggregated Age/Sex disaggregates 2015 2,487
TX_NEW Aggregated Grouping by Age: <1 Male 2015 2
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 2
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 16
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 17
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 402
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 181
TX_NEW Breastfeeding status 2015 20
TX_NEW By Age/Sex: <1 Female 2015 2
TX_NEW By Age/Sex: <1 Male 2015 2
TX_NEW By Age/Sex: 1-4 Female 2015 3
TX_NEW By Age/Sex: 1-4 Male 2015 3
TX_NEW By Age/Sex: 10-14 Female 2015 6
TX_NEW By Age/Sex: 10-14 Male 2015 7
TX_NEW By Age/Sex: 15-19 Female 2015 60
TX_NEW By Age/Sex: 15-19 Male 2015 27
TX_NEW By Age/Sex: 20-24 Female 2015 101
TX_NEW By Age/Sex: 20-24 Male 2015 45
TX_NEW By Age/Sex: 25-49 Female 2015 161
TX_NEW By Age/Sex: 25-49 Male 2015 72
TX_NEW By Age/Sex: 5-9 Female 2015 4
TX_NEW By Age/Sex: 5-9 Male 2015 4
TX_NEW By Age/Sex: 50+ Female 2015 83
TX_NEW By Age/Sex: 50+ Male 2015 36
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 616
TX_NEW Pregnancy status 2015 32
TX_NEW Sum of Age/Sex disaggregates 2015 616
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 616
TX_RET Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 19
TX_RET Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 893
TX_RET Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 28
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 47
TX_RET Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 893
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 940
TX_RET Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2015 442
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 1,106
TX_RET_den Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 22
TX_RET_den Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,051
TX_RET_den Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 33
TX_RET_den Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 55
TX_RET_den Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 1,051
TX_RET_den Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2015 52
Cross Cutting Budget Categories and Known Amounts Total: $11,000
Renovation $10,000
Gender: Gender Based Violence (GBV) $1,000
GBV Prevention
Capacity building
Key Issues Identified in Mechanism
Child Survival Activities
Mobile Populations
Safe Motherhood
Tuberculosis
Workplace Programs
End-of-Program Evaluation
Family Planning